More clinical trials should combine radiotherapy with promising new cancer drugs

The American Society for Radiation Oncology (ASTRO) today issued the following statement in support of findings from an ASTRO-commissioned task force to review opportunities to improve outcomes for cancer patients by expanding the number of clinical trials that include radiotherapy in combination with new cancer drugs. The recommendations were published in the May 2018 issue of The Lancet-Oncology.